Galderma’s Q1 Record Sales Hit $1B+, 12.4% YoY Growth

Galderma Group AG (SWX:GALD), the leading company specializing in dermatology, has announced its sales performance for the first quarter of 2024.

The company achieved record net sales of $1.071 billion during this period, surpassing the $1 billion mark for the first time in a three-month period. Year-on-year net sales growth, based on constant currency, reached 12.4%, primarily attributed to increased volume.

Sales growth was observed across all product categories, with significant increases in Injectable Aesthetics (19.3%), Dermatological Skincare (8.4%), and Therapeutic Dermatology (4.1%) on a constant currency basis. Growth was also evident across various geographical markets, especially in international markets, with accelerated growth in the U.S.

Galderma confirmed its full-year guidance for 2024, projecting a 7-10% year-on-year growth in net sales at constant currency and a Core EBITDA margin consistent with 2023.

The company continues to execute its integrated dermatology strategy, focusing on innovation, commercial execution, and market-leading education and services. Notable achievements include the launch of new products like Cetaphil’s Healthy Renew anti-aging skincare range and Sculptra’s introduction in Thailand.

Galderma’s listing as GALD on the SIX Swiss Exchange since March 22, 2024, following its initial public offering, marks a significant milestone for the company. Strong commercial performance and a commitment to Environmental, Social, and Governance (ESG) principles further underline Galderma’s strategic direction and growth trajectory.

Source Link